Search: id:"swepub:oai:lup.lub.lu.se:11d61d1f-088e-4972-9e00-51461ef72484" >
Intensive lipid low...
Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis
-
Rossebo, Anne B. (author)
-
Pedersen, Terje R. (author)
-
- Boman, Kurt (author)
- Umeå universitet,Medicin
-
show more...
-
Brudi, Philippe (author)
-
Chambers, John B. (author)
-
Egstrup, Kenneth (author)
-
Gerdts, Eva (author)
-
Gohlke-Barwolf, Christa (author)
-
Holme, Ingar (author)
-
Kesaniemi, Y. Antero (author)
-
Malbecq, William (author)
-
Nienaber, Christoph A. (author)
-
Ray, Simon (author)
-
Skjaerpe, Terje (author)
-
Wachtell, Kristian (author)
-
- Willenheimer, Ronnie (author)
- Lund University,Lunds universitet,Kardiologiska klinikens forskargrupp,Forskargrupper vid Lunds universitet,Cardiology Research Group,Lund University Research Groups
-
show less...
-
(creator_code:org_t)
- 2008
- 2008
- English.
-
In: New England Journal of Medicine. - 0028-4793 .- 1533-4406. ; 359:13, s. 1343-1356
- Related links:
-
http://dx.doi.org/10...
-
show more...
-
https://lup.lub.lu.s...
-
https://doi.org/10.1...
-
https://urn.kb.se/re...
-
show less...
Abstract
Subject headings
Close
- Background: Hyperlipidemia has been suggested as a risk factor for stenosis of the aortic valve, but lipid-lowering studies have had conflicting results. Methods: We conducted a randomized, double-blind trial involving 1873 patients with mild-to-moderate, asymptomatic aortic stenosis. The patients received either 40 mg of simvastatin plus 10 mg of ezetimibe or placebo daily. The primary outcome was a composite of major cardiovascular events, including death from cardiovascular causes, aortic-valve replacement, nonfatal myocardial infarction, hospitalization for unstable angina pectoris, heart failure, coronary-artery bypass grafting, percutaneous coronary intervention, and nonhemorrhagic stroke. Secondary outcomes were events related to aortic-valve stenosis and ischemic cardiovascular events. Results: During a median follow-up of 52.2 months, the primary outcome occurred in 333 patients (35.3%) in the simvastatin-ezetimibe group and in 355 patients (38.2%) in the placebo group (hazard ratio in the simvastatin-ezetimibe group, 0.96; 95% confidence interval [CI], 0.83 to 1.12; P=0.59). Aortic-valve replacement was performed in 267 patients (28.3%) in the simvastatin-ezetimibe group and in 278 patients (29.9%) in the placebo group (hazard ratio, 1.00; 95% CI, 0.84 to 1.18; P=0.97). Fewer patients had ischemic cardiovascular events in the simvastatin-ezetimibe group (148 patients) than in the placebo group (187 patients) (hazard ratio, 0.78; 95% CI, 0.63 to 0.97; P=0.02), mainly because of the smaller number of patients who underwent coronary-artery bypass grafting. Cancer occurred more frequently in the simvastatin-ezetimibe group (105 vs. 70, P=0.01). Conclusions: Simvastatin and ezetimibe did not reduce the composite outcome of combined aortic-valve events and ischemic events in patients with aortic stenosis. Such therapy reduced the incidence of ischemic cardiovascular events but not events related to aortic-valve stenosis. (ClinicalTrials.gov number, NCT00092677.).
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Kardiologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cardiac and Cardiovascular Systems (hsv//eng)
Publication and Content Type
- art (subject category)
- ref (subject category)
Find in a library
To the university's database
- By the author/editor
-
Rossebo, Anne B.
-
Pedersen, Terje ...
-
Boman, Kurt
-
Brudi, Philippe
-
Chambers, John B ...
-
Egstrup, Kenneth
-
show more...
-
Gerdts, Eva
-
Gohlke-Barwolf, ...
-
Holme, Ingar
-
Kesaniemi, Y. An ...
-
Malbecq, William
-
Nienaber, Christ ...
-
Ray, Simon
-
Skjaerpe, Terje
-
Wachtell, Kristi ...
-
Willenheimer, Ro ...
-
show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Clinical Medicin ...
-
and Cardiac and Card ...
- Articles in the publication
-
New England Jour ...
- By the university
-
Lund University
-
Umeå University